GSTM1 and lung cancer: Our meta-analysis suggests that the lung cancer patients bearing the favorable GSTM1 null genotype were more likely to have better response rates to platinum-based chemotherapy compared to those with the unfavorable GSTM1 present genotype in Asian patients, but not in Caucasian patients (Table 5 and Fig. 3).